Re: WuXi VIR Alnylam combo may be driving the share price this week.
The work with WuXi is for Vir's antibody approach. Alnylam's siRNAs won't be ready until near the end the year. From an investment standpoint, I don't think they really matter except maybe as a proof of concept for lung delivery.
Lots of biotech stocks ran up today, I don't think it was anything Alnylam specific. Something to do with rebalancing of indexes. Regeneron jumped almost 8%. Heck, even Biogen popped 4%.